Table 2.

Distribution of antihypertensive substances in hypertension patients in the SHIP-0 cohort¹to SHIP-1

	Females (N = 509)		Males (N = 565)		Total (N = 1074)
Active agents	N	% (95% CI2)	N	% (95% CI2)	N	% (95% CI2)
Beta blockers	335	66.2	336	61.2	671	63.7
		(61.8 – 70.5)		(56.8 – 65.5)		(60.6 – 66.8)
ACE-inhibitors	252	49.6	334	55.3	586	52.4
		(45.0 – 54.2)		(50.9 – 59.7)		(49.2 – 55.6)
Diuretics	242	45.0	233	37.2	475	41.1
		(40.7 – 49.4)		(32.7 – 41.7)		(38.0 – 44.3)
Calcium channel blocker	160	28.9	187	32.3	347	30.6
		(24.9 – 32.9)		(28.0 – 36.7)		(27.6 – 33.6)
Angiotensin II receptor antagonists	108	20.1	98	17.3	206	18.7
		(16.4 – 23.8)		(13.9 – 20.6)		(16.2 – 21.2)
Antiadrenergic substances3	22	4.4	34	5.4	56	4.9
		(2.5 – 6.3)		(3.2 – 7.7)		(3.4 – 6.4)
Vasodilators4	2	0.3	1	0.2	3	0.2
		(0.0 – 0.8)		(0.0 – 0.5)		(0.0 – 0.5)
Other types	-	-	1	0.2	1	0.1
				(0.0 – 0.6)		(0.0 – 0.3)

¹Study participants with blood pressure values ≥140/90 mmHg and/or antihypertensive medication with known hypertension and/or study participants with risk-comorbidity (diabetes, stroke, angina pectoris, and/or myocardial infarction) and blood pressure values ≥130/80 mmHg.

²CI confidence interval.

³Both peripheral and central active antiadrenergic substances.

⁴Only with indication hypertension.